Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
01
06
2022
accepted:
05
08
2022
pubmed:
19
8
2022
medline:
28
1
2023
entrez:
18
8
2022
Statut:
ppublish
Résumé
The natural history of hepatocellular adenomas (HCAs) remains to be better described, especially in nonresected patients. We aim to identify the predictive factors of HCA evolution after estrogen-based contraception discontinuation. We retrospectively included patients with a histological diagnosis of HCA from three centers. Clinical, radiological, and pathological data were collected to identify predictive factors of radiological evolution per Response Evaluation Criteria in Solid Tumors, version 1.1, and occurrence of complications (bleeding, malignant transformation). We built a score using variables that modulate estrogen levels: body mass index and duration of estrogen-based contraception. An external cohort was used to validate this score. 183 patients were included in the cohort, including 161 women (89%) using estrogen-based contraception for a median of 12 years. Thirty percent of patients had at least one HNF1A -inactivated HCA, 45.5% at least one inflammatory HCA, and 11% at least one HCA with activation of β-catenin (bHCA). Twenty-one symptomatic bleedings (11%) and eleven malignant transformations (6%) occurred. Ages < 37 years old ( p = 0.004) and HCA > 5 cm at imaging were independently associated with symptomatic bleeding ( p = 0.003), whereas a bHCA was associated with malignant transformation ( p < 0.001). After a median follow-up of 5 years, radiological regression was observed in 31%, stabilization in 47%, and progression in 22% of patients. Weight loss was associated with regression ( p < 0.0001) and weight gain with progression ( p = 0.02). The estrogen exposure score predicted radiological regression (odds ratio, 2.33; confidence interval 95%, 1.29-4.19; p = 0.005) with a linear relationship between the rate of estrogen exposure and the probability of regression. This result was confirmed in an external cohort of 72 female patients ( p = 0.003). Weight variation is strongly associated with radiological evolution after oral contraception discontinuation. A score of estrogen exposure, easily assessable in clinical practice at diagnosis, predicts regression of HCA.
Sections du résumé
BACKGROUND AND AIMS
The natural history of hepatocellular adenomas (HCAs) remains to be better described, especially in nonresected patients. We aim to identify the predictive factors of HCA evolution after estrogen-based contraception discontinuation.
APPROACH AND RESULTS
We retrospectively included patients with a histological diagnosis of HCA from three centers. Clinical, radiological, and pathological data were collected to identify predictive factors of radiological evolution per Response Evaluation Criteria in Solid Tumors, version 1.1, and occurrence of complications (bleeding, malignant transformation). We built a score using variables that modulate estrogen levels: body mass index and duration of estrogen-based contraception. An external cohort was used to validate this score. 183 patients were included in the cohort, including 161 women (89%) using estrogen-based contraception for a median of 12 years. Thirty percent of patients had at least one HNF1A -inactivated HCA, 45.5% at least one inflammatory HCA, and 11% at least one HCA with activation of β-catenin (bHCA). Twenty-one symptomatic bleedings (11%) and eleven malignant transformations (6%) occurred. Ages < 37 years old ( p = 0.004) and HCA > 5 cm at imaging were independently associated with symptomatic bleeding ( p = 0.003), whereas a bHCA was associated with malignant transformation ( p < 0.001). After a median follow-up of 5 years, radiological regression was observed in 31%, stabilization in 47%, and progression in 22% of patients. Weight loss was associated with regression ( p < 0.0001) and weight gain with progression ( p = 0.02). The estrogen exposure score predicted radiological regression (odds ratio, 2.33; confidence interval 95%, 1.29-4.19; p = 0.005) with a linear relationship between the rate of estrogen exposure and the probability of regression. This result was confirmed in an external cohort of 72 female patients ( p = 0.003).
CONCLUSION
Weight variation is strongly associated with radiological evolution after oral contraception discontinuation. A score of estrogen exposure, easily assessable in clinical practice at diagnosis, predicts regression of HCA.
Identifiants
pubmed: 35980227
pii: 01515467-202302000-00012
doi: 10.1002/hep.32734
doi:
Substances chimiques
Contraceptives, Oral, Hormonal
0
Estrogens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
430-442Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman‐Rossi J. Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol. 2017;67:1074–83. https://doi.org/10.1016/j.jhep.2017.07.009
doi: 10.1016/j.jhep.2017.07.009
Bieze M, Phoa SSKS, Verheij J, van Lienden KP, van Gulik TM. Risk factors for bleeding in hepatocellular adenoma. Br J Surg. 2014;101:847–55. https://doi.org/10.1002/bjs.9493
doi: 10.1002/bjs.9493
Julien C, Le‐Bail B, Ouazzani Touhami K, Frulio N, Blanc JF, Adam JP, et al. Hepatocellular adenoma risk factors of hemorrhage: size is not the only concern!: Single‐center retrospective experience of 261 patients. Ann Surg. 2021;274:843–50. https://doi.org/10.1097/SLA.0000000000005108
doi: 10.1097/SLA.0000000000005108
Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017;152:880–94.e6. https://doi.org/10.1053/j.gastro.2016.11.042
doi: 10.1053/j.gastro.2016.11.042
Laurent A, Dokmak S, Nault JC, Pruvot FR, Fabre JM, Letoublon C, et al. European experience of 573 liver resections for hepatocellular adenoma: a cross‐sectional study by the AFC‐HCA‐2013 study group. HPB (Oxford). 2016;18:748–55. https://doi.org/10.1016/j.hpb.2016.06.011
doi: 10.1016/j.hpb.2016.06.011
van Aalten SM, de Man RA, JNM I, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg. 2012;99:911–6. https://doi.org/10.1002/bjs.8762
doi: 10.1002/bjs.8762
Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single‐center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698–705. https://doi.org/10.1053/j.gastro.2009.07.061
doi: 10.1053/j.gastro.2009.07.061
van Aalten SM, Witjes CD, de Man RA, Ijzermans JNM, Terkivatan T. Can a decision‐making model be justified in the management of hepatocellular adenoma? Liver Int. 2012;32:28–37. https://doi.org/10.1111/j.1478‐3231.2011.02667.x
doi: 10.1111/j.1478-3231.2011.02667.x
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol. 2016;65:386–98. https://doi.org/10.1016/j.jhep.2016.04.001
doi: 10.1016/j.jhep.2016.04.001
Zucman‐Rossi J, Jeannot E, Nhieu JTV, Scoazec JY, Guettier C, Rebouissou S, et al. Genotype‐phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515–24. https://doi.org/10.1002/hep.21068
doi: 10.1002/hep.21068
Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK‐activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428–41. https://doi.org/10.1016/j.ccr.2014.03.005
doi: 10.1016/j.ccr.2014.03.005
Vernuccio F, Ronot M, Dioguardi Burgio M, Cauchy F, Choudhury KR, Dokmak S, et al. Long‐term evolution of hepatocellular adenomas at MRI follow‐up. Radiology. 2020;292:361–72. https://doi.org/10.1148/radiol.2020191790
doi: 10.1148/radiol.2020191790
Klompenhouwer AJ, Alblas M, Vivica van Rosmalen B, Haring MPD, Venema E, Doukas M, et al. Development and validation of a model to predict regression of large size hepatocellular adenoma. Am J Gastroenterol. 2019;114:1292–8. https://doi.org/10.14309/ajg.0000000000000182
doi: 10.14309/ajg.0000000000000182
Klompenhouwer AJ, van Rosmalen BV, Haring MPD, Thomeer MGJ, Doukas M, Verheij J, et al. A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection. Liver Int. 2020;40:2272–8. https://doi.org/10.1111/liv.14467
doi: 10.1111/liv.14467
Klompenhouwer AJ, Bröker MEE, Thomeer MGJ, Gaspersz MP, de Man RA. Retrospective study on timing of resection of hepatocellular adenoma. Br J Surg. 2017;104:1695–703. https://doi.org/10.1002/bjs.10594
doi: 10.1002/bjs.10594
Bioulac‐Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740–8. https://doi.org/10.1002/hep.21743
doi: 10.1002/hep.21743
Chopinet S, Cauchy F, Hobeika C, Beaufrère A, Poté N, Farges O, et al. Long‐term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas. JHEP Rep. 2021;3:100326. https://doi.org/10.1016/j.jhepr.2021.100326
doi: 10.1016/j.jhepr.2021.100326
Horn DB, Almandoz JP, Look M. What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. Postgrad Med. 2022;134:359–75. https://doi.org/10.1080/00325481.2022.2051366
doi: 10.1080/00325481.2022.2051366
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023. https://doi.org/10.1016/j.jacc.2013.11.004
doi: 10.1016/j.jacc.2013.11.004
Brown KA, Simpson ER. Estrogens, obesity, inflammation, and breast cancer–what is the link? Semin Reprod Med. 2015;33:208–12. https://doi.org/10.1055/s‐0035‐1552581
doi: 10.1055/s-0035-1552581
Brown KA. Impact of obesity on mammary gland inflammation and local estrogen production. J Mammary Gland Biol Neoplasia. 2014;19:183–9. https://doi.org/10.1007/s10911‐014‐9321‐0
doi: 10.1007/s10911-014-9321-0
Van der Borght S, Libbrecht L, Katoonizadeh A, Aerts R, Nevens F, Verslype C, et al. Nuclear beta‐catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology. 2007;51:855–6. https://doi.org/10.1111/j.1365‐2559.2007.02862.x
doi: 10.1111/j.1365-2559.2007.02862.x
Sempoux C, Bisig B, Couchy G, Balabaud C, Zucman‐Rossi J, Bioulac‐Sage P. Malignant transformation of a β‐catenin inflammatory adenoma due to an S45 β‐catenin‐activating mutation present 12 years before. Hum Pathol. 2017;62:122–5. https://doi.org/10.1016/j.humpath.2016.10.004
doi: 10.1016/j.humpath.2016.10.004
Bioulac‐Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50:481–9. https://doi.org/10.1002/hep.22995
doi: 10.1002/hep.22995
Gevers TJG, Marcel Spanier BW, Veendrick PB, Vrolijk JM. Regression of hepatocellular adenoma after bariatric surgery in severe obese patients. Liver Int. 2018;38:2134–6. https://doi.org/10.1111/liv.13934
doi: 10.1111/liv.13934
Dokmak S, Belghiti J. Will weight loss become a future treatment of hepatocellular adenoma in obese patients? Liver Int. 2015;35:2228–32. https://doi.org/10.1111/liv.12925
doi: 10.1111/liv.12925
Oudmaijer CAJ, Berk KA, van der Louw EJTM, de Man R, van der Lelij AJ, Hoeijmakers JHJ, et al. KETOgenic diet therapy in patients with HEPatocellular adenoma: study protocol of a matched interventional cohort study. BMJ Open. 2022;12:e053559. https://doi.org/10.1136/bmjopen‐2021‐053559
doi: 10.1136/bmjopen-2021-053559
Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, et al. Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression. Hepatology. 2016;64:2047–61.